TCR-like antibodies in cancer immunotherapy
- PMID: 31521180
- PMCID: PMC6744646
- DOI: 10.1186/s13045-019-0788-4
TCR-like antibodies in cancer immunotherapy
Abstract
Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.
Keywords: Antibody; Immunotherapy; T cell receptor; TCR-like antibody; Tumor antigen.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity.Front Immunol. 2024 Nov 22;15:1486721. doi: 10.3389/fimmu.2024.1486721. eCollection 2024. Front Immunol. 2024. PMID: 39650646 Free PMC article. Review.
-
Genetic engineering of T cell specificity for immunotherapy of cancer.Hum Immunol. 2003 Jan;64(1):56-68. doi: 10.1016/s0198-8859(02)00730-9. Hum Immunol. 2003. PMID: 12507815 Review.
-
T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. doi: 10.1586/14737140.5.3.523. Expert Rev Anticancer Ther. 2005. PMID: 16250828 Review.
-
Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.J Mol Recognit. 2003 Sep-Oct;16(5):324-32. doi: 10.1002/jmr.640. J Mol Recognit. 2003. PMID: 14523945 Review.
-
Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.J Immunol. 1993 Mar 15;150(6):2211-21. J Immunol. 1993. PMID: 8450208
Cited by
-
CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy.Adv Pharm Bull. 2022 May;12(3):476-489. doi: 10.34172/apb.2022.051. Epub 2021 Aug 22. Adv Pharm Bull. 2022. PMID: 35935042 Free PMC article. Review.
-
CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91/HLA-A *0201 exhibit potent activity against HBV-HCC.Oncoimmunology. 2025 Dec;14(1):2546404. doi: 10.1080/2162402X.2025.2546404. Epub 2025 Aug 18. Oncoimmunology. 2025. PMID: 40820888 Free PMC article.
-
Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.Front Oncol. 2022 Feb 9;12:769124. doi: 10.3389/fonc.2022.769124. eCollection 2022. Front Oncol. 2022. PMID: 35223466 Free PMC article. Review.
-
Novel strategies for immuno-oncology breakthroughs with cell therapy.Biomark Res. 2021 Jul 31;9(1):62. doi: 10.1186/s40364-021-00316-6. Biomark Res. 2021. PMID: 34332618 Free PMC article. Review.
-
Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.Cancer Sci. 2020 Oct;111(10):3516-3526. doi: 10.1111/cas.14602. Epub 2020 Aug 26. Cancer Sci. 2020. PMID: 32770595 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials